Press Releases
- Connie Ryan announces retirement from StreckConnie Ryan announces retirement from Streck La Vista, Nebraska – After 42 years of dedicated service, Connie Ryan has announced her retirement from Streck. Since joining the company in 1982,… Read more: Connie Ryan announces retirement from Streck
- Streck to distribute Ceres NEAT Liquid Biopsy Kit – Streck BCT worldwideStreck to distribute Ceres NEAT Liquid Biopsy Kit – Streck BCT worldwide La Vista, Nebraska – Streck is pleased to announce an expanded partnership with Ceres Nanosciences (Ceres) to distribute… Read more: Streck to distribute Ceres NEAT Liquid Biopsy Kit – Streck BCT worldwide
- Streck establishes partnership with Longhorn Vaccines and Diagnostics to distribute PrimeStore® MTM worldwideStreck establishes partnership with Longhorn Vaccines and Diagnostics to distribute PrimeStore® MTM worldwide La Vista, Nebraska – Streck is pleased to announce its new partnership with Longhorn Vaccines and Diagnostics… Read more: Streck establishes partnership with Longhorn Vaccines and Diagnostics to distribute PrimeStore® MTM worldwide
- Streck Announces Partnership with Longhorn Vaccines and DiagnosticsStreck Announces Partnership with Longhorn Vaccines and Diagnostics La Vista, Nebraska – Streck is pleased to announce its new distribution partnership with Longhorn Vaccines and Diagnostics. The partnership is a… Read more: Streck Announces Partnership with Longhorn Vaccines and Diagnostics
- Streck launches Protein Plus BCT for stabilization of plasma proteins in whole bloodStreck launches Protein Plus BCT for stabilization of plasma proteins in whole blood La Vista, Nebraska – Streck is pleased to announce the launch of Protein Plus BCTTM,… Read more: Streck launches Protein Plus BCT for stabilization of plasma proteins in whole blood
- MDx-Chex for BC-GP and BC-GN LaunchMDx-Chex® for BC-GP and BC-GN, new full-process, molecular diagnostics quality controls for bloodstream infections, receive FDA clearance La Vista, Nebraska – Streck is pleased to announce that MDx-Chex® for BC-GP… Read more: MDx-Chex for BC-GP and BC-GN Launch
- Streck Announces Series B Investment in Ceres NanosciencesStreck Announces Series B Investment in Ceres Nanosciences La Vista, Nebraska – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be… Read more: Streck Announces Series B Investment in Ceres Nanosciences
- Streck introduces viral extraction kit for clinical samplesStreck introduces viral extraction kit for clinical samples La Vista, NE – Streck is pleased to announce the commercialization of Streck® Viral Extraction Kit with partner Ceres Nanosciences. Streck has… Read more: Streck introduces viral extraction kit for clinical samples
- Streck’s first-of-its-kind molecular diagnostics quality control MDx-Chex for BCID2 receives FDA clearanceStreck’s first-of-its-kind molecular diagnostics quality control MDx-Chex for BCID2 receives FDA clearance La Vista, NE –Streck is pleased to announce MDx-Chex™ for BCID2, a first-of-its-kind quality control designed to meet… Read more: Streck’s first-of-its-kind molecular diagnostics quality control MDx-Chex for BCID2 receives FDA clearance
- Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solutionStreck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution La Vista, NE –Streck is pleased to announce the partnership with Ceres Nanosciences to distribute Nanotrap® Magnetic Virus… Read more: Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution
- Streck launches first-of-its-kind molecular quality control MDx-Chex for BCID2Streck is pleased to announce MDx-Chex™ for BCID2, a first-of-its-kind quality control designed to meet the standards for verifying the performance of sample-to-result molecular tests for sepsis. MDx-Chex for BCID2 is For Research Use Only. Not for use in diagnostic procedures.
- Streck Cell-Free DNA BCT receives U.S. FDA De Novo clearanceStreck Cell-Free DNA BCT received U.S. Food and Drug Administration De Novo clearance for In Vitro Diagnostic use when paired with the Guardant360 CDx liquid biopsy assay. Cell-Free DNA BCT is the first and only circulating nucleic acid blood collection tube to be cleared for use with liquid biopsy.
- Biodesix Partners with Streck to Support In Vitro Diagnostic (IVD) StrategyBiodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.